MicroRNA-155 regulates the Th17 immune response by targeting Ets-1 in Behcet's disease

作者：Na S Y; Park M J; Park S; Lee E S^*

来源：Clinical and Experimental Rheumatology, 2016, 34(6): S56-S63.

• Behcet's disease
• Th17 cells
• microRNA-155
• Ets-1

Objective. The goal of this study was to investigate whether microRNA-155 might be a potential therapeutic target for Behvet's disease (BD).
Methods. Expression levels of miR-155 were quantified using TaqMan microRNA assays in peripheral blood mononuclear cells and in isolated CD4(+) T cells from BD patients and healthy controls. To identify targets of miR-155, luciferase reporter assays and western blotting were performed. The effect of miR155 on Th17 polarisation was analysed in patients with active BD by using flow cytometry and enzyme-linked immunosorbent assay.
Results. The expression of miR-155 and IL-17 was significantly increased in CD4(+) T cells of patients with active BD. A luciferase reporter assay and western blot showed that Ets-1 expression was reduced by miR-155 mimics. Furthermore, the expression of Ets-1 was significantly decreased in patients with active BD compared to healthy controls. More importantly, repression of miR-155 in CD4(+) T cells from active BD patients increased Ets-1 expression and reduced the number of IL-17-expressing T cells and overall IL-17 production.
Conclusion. MiR-155 regulates the Th17 immune response by targeting Ets1. Suppression of miR-155 reduced the amount of pathogenic IL-17-expressing T cells and may be a potential therapeutic strategy for BD.

• 出版日期2016-12